Konstantinos Tzelepis is a Wellcome Principal Investigator at the Cambridge Stem Cell Institute and the University of Cambridge (UK). Prior to this, he was a Wellcome Trust Sir Henry Wellcome Fellow at Harvard University (USA) and the University of Cambridge (UK). He obtained his Ph.D. in Molecular Genetics from the Wellcome Sanger Institute and the University of Cambridge, in 2017, where he developed one of the first genome-wide CRISPR screening platforms for the identification and therapeutic translation of novel cancer vulnerabilities. His lab is focusing on the mechanistic understanding and therapeutic targeting of RNA and its modifications in cancer and ageing.
Recently, his group co-developed and characterised first-in-class pre-clinical and clinical RNA methyltransferase inhibitors.
